Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy.
about
Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.Adoptive T-Cell Therapy for Solid Tumors.T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy.Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche.Immune Therapy for Prostate Cancer.CAR T-cell therapy for pancreatic cancer.The role of IL-12/23 in T cell-related chronic inflammation: implications of immunodeficiency and therapeutic blockade.Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice.Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment.CAR T cell therapy for multiple myeloma: where are we now and where are we headed?'Atypical' CAR T cells: NKG2D and Erb-B as examples of natural receptor/ligands to target recalcitrant solid tumors.Assembly-induced folding regulates interleukin 12 biogenesis and secretion.The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective.Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.T-bet promotes potent antitumor activity of CD4+ CAR T cells.Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of Glioma.Synthetic immunology: T-cell engineering and adoptive immunotherapyNew developments in immunotherapy for lymphoma
P2860
Q33823270-D5A401E5-514A-4774-B9FE-0E76B73D058CQ38754498-7AF06344-A69E-440D-B14D-E8BB6F3D86A0Q38873974-BB362465-91C6-4F7F-814F-42EA69E6BB63Q38932298-B7A1B215-EA20-46D9-8719-34DA4B5BAF31Q38982667-2764151A-E901-42DF-B8F5-67152088EBEAQ39202440-38D71DC0-BE43-40F4-84DD-0D2C5718A94BQ39328684-8329DE84-AC8B-4280-9A27-C0181482F215Q39401736-BA8BAAA3-CFAC-4001-9D3D-E6D8FED91B02Q41619752-CF648618-6C10-4C75-AE3C-5D169AC40294Q47565827-88110878-775B-4B06-8830-D7CE8AED3C9FQ47849932-75A8026E-4AB7-4B92-B4FA-1B82F736E6EEQ48096038-7013333A-E784-4D81-B231-9B8B06A5651FQ50033731-EC0823CF-70D0-468D-8F37-0C74B4E333EAQ50531950-B7C54DB4-35D2-4BD6-90D2-DEBC4F6D15AAQ52668512-864B5B8B-B778-4867-B2FE-17B47B4E385AQ55224144-7E6EE353-719D-4D14-8719-B98B511FAC0DQ57823195-107F39CF-6813-4EC8-843A-244450B2614FQ58804962-7A211122-D614-4101-BC14-5FDB7E3FACF8
P2860
Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Armored CAR T-cells: utilizing ...... R T-cell anti-tumour efficacy.
@en
type
label
Armored CAR T-cells: utilizing ...... R T-cell anti-tumour efficacy.
@en
prefLabel
Armored CAR T-cells: utilizing ...... R T-cell anti-tumour efficacy.
@en
P2860
P356
P1476
Armored CAR T-cells: utilizing ...... R T-cell anti-tumour efficacy.
@en
P2093
Oladapo O Yeku
Renier J Brentjens
P2860
P304
P356
10.1042/BST20150291
P577
2016-04-01T00:00:00Z